Candidate single nucleotide polymorphism markers for arsenic responsiveness of protein targets

Bioinformatics and Biology Insights

Volumn 4, Issue , 2010, Pages 99-111

  Isokpehi, Raphael D ^a   Cohly, Hari H P ^a   Anyanwu, Matthew N ^a,b   Rajnarayanan, Rajendram V ^c   Tchounwou, Paul B ^a   Udensi, Udensi K ^a   Graham Evans, Barbara E ^a  

^a Jackson State University   (United States)

^b University of Memphis   (United States)

^c UNIVERSITY AT BUFFALO   (United States)

Author keywords

Arsenic; Keratinocytes; Non synonymous single nucleotide polymorphisms; Skin cancer; Toxicogenomics; Vicinal cysteines

Indexed keywords

ARSENIC; CYSTEINE; SERINE PROTEINASE; STRATUM CORNEUM CHYMOTRYPTIC ENZYME;

AMINO ACID SUBSTITUTION; ARTICLE; BINDING SITE; DISULFIDE BOND; ENZYME ACTIVITY; EPIDERMIS; GENE IDENTIFICATION; GENETIC LINKAGE; KERATINOCYTE; MOLECULAR MECHANICS; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION; PROTEIN TARGETING; SINGLE NUCLEOTIDE POLYMORPHISM; SKIN CANCER; SKIN CARCINOGENESIS; TOXICOGENETICS;

EID: 78649988294     PISSN: None     EISSN: 11779322     Source Type: Journal    
DOI: 10.4137/bbi.s5498     Document Type: Article

References (48)

1. Hall M, Chen Y, Ahsan H, et al. Blood arsenic as a biomarker of arsenic exposure: results from a prospective study. Toxicology. 2006;225:225-33
2. Tchounwou PB, Patlolla AK, Centeno JA. Carcinogenic and systemic health effects associated with arsenic exposure-a critical review. Toxicologic Pathology. 2003;31:575-88
3. Ding W, Hudson LG, Liu KJ. Inorganic arsenic compounds cause oxidative damage to DNA and protein by inducing ROS and RNS generation in human keratinocytes. Molecular and Cellular Biochemistry. 2005;279:105-12
4. Pi J, He Y, Bortner C, et al. Low level, long-term inorganic arsenite exposure causes generalized resistance to apoptosis in cultured human keratinocytes: potential role in skin co-carcinogenesis. International Journal of Cancer. 2005;116:20-6.
5. Tchounwou PB, Centeno JA, Patlolla AK. Arsenic toxicity, mutagenesis, and carcinogenesis-a health risk assessment and management approach. Molecular and Cellular Biochemistry. 2004;255:47-55.
6. Mead MN. Arsenic: in search of an antidote to a global poison. Environmental Health Perspectives. 2005;113:A378-86
7. McDonald C, Hoque R, Huda N, Cherry N. Prevalence of arsenic-related skin lesions in 53 widely-scattered villages of Bangladesh: an ecological survey Journal of Health and Population Nutrition. 2006;24:228-35
8. Meliker JR, Wahl RL, Cameron LL, Nriagu JO. Arsenic in drinking water and cerebrovascular disease, diabetes mellitus, and kidney disease in Michigan: a standardized mortality ratio analysis. Environmental Health. 2007;6:4
9. U.S. EPA (U.S. Environmental Protection Agency). National primary drinking water regulations: arsenic and clarifications to compliance and new source contaminants monitoring. Final Rule. Federal Register. 2001;66:6976-7066
10. Hughes MF. Biomarkers of exposure: a case study with inorganic arsenic. Environmental Health Perspectives. 2006;114:1790-6
11. Centeno JA, Mullick FG, Martinez L, et al. Pathology related to chronic arsenic exposure. Environmental Health Perspectives. 2002;110 Suppl 5 883-6
12. Lansdown AB. Physiological and toxicological changes in the skin resulting from the action and interaction of metal ions. Critical Reviews in Toxicology. 1995;25:397-462
13. Ralph SJ. Arsenic-based antineoplastic drugs and their mechanisms of action. Metal Based Drugs. 2008;2008:260146.
14. Bates MN, Smith AH, Hopenhayn-Rich C. Arsenic ingestion and internal cancers: a review. American Journal of Epidemiology. 1992;135:462-76
15. Yu HS, Liao WT, Chai CY. Arsenic carcinogenesis in the skin. Journal of Biomedical Science. 2006;13:657-66
16. Soignet SL, Maslak P, Wang ZG, et al. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. New England Journal of Medicine. 1998;339:1341-8
17. Yedjou C, Thuisseu L, Tchounwou C, et al. Ascorbic acid potentiation of arsenic trioxide anticancer activity against acute promyelocytic leukemia. Archives of Drug Information. 2009;2:59-65
18. Yedjou CG, Moore P, Tchounwou PB. Dose- and time-dependent response of human leukemia (HL-60) cells to arsenic trioxide treatment. International Journal of Environmental Research and Public Health. 2006;3:136-40
19. Yedjou CG, Tchounwou PB. In-vitro cytotoxic and genotoxic effects of arsenic trioxide on human leukemia (HL-60) cells using the MTT and alkaline single cell gel electrophoresis (Comet) assays. Molecular and Cellular Biochemistry. 2007;301:123-30.
20. Yedjou CG, Rogers C, Brown E, Tchounwou PB. Differential effect of ascorbic acid and n-acetyl-L-cysteine on arsenic trioxide-mediated oxidative stress in human leukemia (HL-60) cells. Journal of Biochemical and Molecular Toxicology. 2008;22:85-92
21. Raghu KG, Yadav GK, Singh R, et al. Evaluation of adverse cardiac effects induced by arsenic trioxide, a potent anti-APL drug. Journal of Environmental Pathology, Toxicology and Oncology. 2009;28:241-52
22. Breton CV, Zhou W, Kile ML, et al. Susceptibility to arsenic-induced skin lesions from polymorphisms in base excision repair genes. Carcinogenesis. 2007;28:1520-5
23. Yamada R. Primer: SNP-associated studies and what they can teach us. Nature Clinical Practice Rheumatology. 2008;4:210-7.
24. Sherry ST, Ward MH, Kholodov M, et al. dbSNP: the NCBI database of genetic variation. Nucleic Acids Research. 2001;29:308-11.
25. Ng PC, Henikoff S. Predicting the effects of amino acid substitutions on protein function. Annual Review of Genomics and Human Genetics. 2006; 61-80
26. Clifford RJ, Edmonson MN, Nguyen C, et al. Bioinformatics tools for single nucleotide polymorphism discovery and analysis. Annals of the New York Academy of Sciences. 2004;1020:101-9.
27. Kang JQ, Macdonald RL. Making sense of nonsense GABA(A) receptor mutations associated with genetic epilepsies. Trends in Molecular Medicine. 2009;15:430-8.
28. Mukherjee B, Salavaggione OE, Pelleymounter LL, et al. Glutathione S-transferase omega 1 and omega 2 pharmacogenomics. Drug Metabolism and Disposition: The Biological Fate of Chemical. 2006;34:1237-46
29. Shen ZX, Chen GQ, Ni JH, et al. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood. 1997;89:3354-60.
30. Mizumura A, Watanabe T, Kobayashi Y, Hirano S. Identification of arseniteand arsenic diglutathione-binding proteins in human hepatocarcinoma cells. Toxicology and Applied Pharmacology. 2010;242:119-25
31. Ramadan D, Rancy PC, Nagarkar RP, Schneider JP, Thorpe C. Arsenic (III) species inhibit oxidative protein folding in vitro. Biochemistry. 2009; 424-32
32. Zhang X, Yang F, Shim JY, et al. Identification of arsenic-binding proteins in human breast cancer cells. Cancer Letters. 2007;255:95-106.
33. Song X, Geng Z, Zhu J, et al. Structure-function roles of four cysteine residues in the human arsenic (?3 oxidation state) methyltransferase (hAS3MT) by sitedirected mutagenesis. Chemico-Biological Interactions. 2009;179:321-8.
34. He X, Ma Q. Critical cysteine residues of Kelch-like ECH-associated protein 1 in arsenic sensing and suppression of nuclear factor erythroid 2- related factor 2. Journal of Pharmacology and Experimental Therapeutics. 2010;332:66-75.
35. Davis AP, Murphy CG, Rosenstein MC, Wiegers TC, Mattingly CJ. The Comparative Toxicogenomics Database facilitates identification and understanding of chemical-gene-disease associations: arsenic as a case study. BMC Medical Genomics. 2008;1:48.
36. Yue P, Melamud E, Moult J. SNPs3D: candidate gene and SNP selection for association studies. BMC Bioinformatics. 2006;7:166.
37. Sayers EW, Barrett T, Benson DA, et al. Database resources of the National Center for Biotechnology Information. Nucleic Acids Research 2009;37:D5-15
38. Yue P, Moult J. Identification and analysis of deleterious human SNPs. Journal of Molecular Biology.2006;356:1263-74.
39. Marti-Renom MA, Stuart AC, Fiser A, et al. Comparative protein structure modeling of genes and genomes. Annual Review of Biophysics and Biomolecular Structure. 2000;29:291-325.
40. Kouranov A, Xie L, de la Cruz J, et al. The RCSB PDB information portal for structural genomics. Nucleic Acids Research. 2006;34:302-5.
41. Bae DS, Hanneman WH, Yang RS, Campain JA. Characterization of gene expression changes associated with MNNG, arsenic, or metal mixture treatment in human keratinocytes: application of cDNA microarray technology. Environmental Health Perspectives. 2002;110 Suppl 931-41.
42. Mukherjee B, Salavaggione OE, Pelleymounter LL, et al. Glutathione S-transferase omega 1 and omega 2 pharmacogenomics. Drug Metabolism and Disposition: The Biological Fate of Chemicals. 2006;34:1237-46.
43. Ferrario D, Croera C, Brustio R, et al. Toxicity of inorganic arsenic and its metabolites on haematopoietic progenitors "in vitro": comparison between species and sexes. Toxicology. 2008;249:102-8.
44. Ekholm IE, Brattsand M, Egelrud T. Stratum corneum tryptic enzyme in normal epidermis: a missing link in the desquamation process? Journal of Investigative Dermatology. 2000;114:56-63.
45. Kitchin KT, Wallace K. Arsenite binding to synthetic peptides based on the Zn finger region and the estrogen binding region of the human estrogen receptor-alpha. Toxicology and Applied Pharmacology. 2005;206:66-72.
46. Pampalakis G, Sotiropoulou G. Tissue kallikrein proteolytic cascade pathways in normal physiology and cancer. Biochimica et Biophysica Acta: Protein Structure and Molecular Enzymology. 2007;1776:22-31.
47. Hachem JP, Man MQ, Crumrine D, et al. Sustained serine proteases activity by prolonged increase in pH leads to degradation of lipid processing enzymes and profound alterations of barrier function and stratum corneum integrity Journal of Investigative Dermatology. 2005;125:510-20.
48. Mukherjee B, Salavaggione OE, Pelleymounter LL, et al. Glutathione S-transferase omega 1 and omega 2 pharmacogenomics. Drug Metabolism and Disposition: The Biological Fate of Chemicals. 2006;34:1237-46.